Methane

Methane

SCHEMBL505763

C.O=C(O)Cc1ccc2oc(-c3ccc(Cl)cc3)nc2c1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 11/20 0.70
KDM4E B2RXH2 2/20 0.63
MAPT P10636 1/20 0.58
MAOA P21397 1/20 0.58
ADRA1A P35348 1/20 0.58
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
ALDH1A1 P00352 1/20 0.56
POLB P06746 1/20 0.56
HPGD P15428 1/20 0.56
PPARG P37231 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HSD17B10 Q99714 1/20 0.56
NR2E3 Q9Y5X4 1/20 0.56
NCOR2 Q9Y618 1/20 0.56
KDR P35968 1/20 0.56
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL25304065 0.99 HPSE (0.69) HPSEKDM4EMAPTMAOAADRA1A
SCHEMBL11626342 0.99 HPSE (0.72) HPSEKDM4EMAPTMAOAADRA1A
Methane SCHEMBL11176675 0.90 HPSE (0.57) HPSEKDM4EMAPTMAOAADRA1A
SCHEMBL5052834 0.87 CASP3 (0.59) HPSEKDM4EMAPTMAOAADRA1A
Methane SCHEMBL506232 0.87 HPSE (0.70) HPSEKDM4EMAPTSMN1; SMN2GAA
Methane SCHEMBL5476423 0.87 HPSE (0.70) HPSEKDM4EMAPTNPC1RAB9A
SCHEMBL507169 0.87 KDM4E (0.77) HPSEKDM4ENPC1RAB9AALDH1A1
SCHEMBL5461475 0.86 HPSE (0.72) HPSEKDM4EMAPTNPC1RAB9A
SCHEMBL9820079 0.86 HPSE (0.72) HPSEKDM4EMAPTSMN1; SMN2GAA
SCHEMBL14581706 0.85 HPSE (0.70) HPSEKDM4ENPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023134733-A1 TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS TECHFIELDS PHARMA CO., LTD. (CN) 2023-07-20 WO claimed
EP-2393771-A1 Method for the synthesis of chiral alpha-aryl propionic acid derivatives DSM IP Assets B.V. (NL) 2011-12-14 EP claimed
WO-2010089343-A1 METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES DSM IP ASSETS B.V. (NL) 2010-08-12 WO claimed
US-4416892-A ANTIALLERGENS LILLY INDUSTRIES LIMITED (GB) 1983-11-22 US claimed
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS TECHFIELDS PHARMA CO., LTD (CN) 2023-07-27 US disclosed
WO-2023134733-A1 TREATMENT OF SIGNS, SYMPTOMS AND/OR COMPLICATIONS OF VIRAL, BACTERIAL, PROTOZOAL, AND/OR FUNGAL INFECTIONS BY HIGH PENETRATION PRODRUGS TECHFIELDS PHARMA CO., LTD. (CN) 2023-07-20 WO disclosed
US-11541029-B2 High penetration compositions and their applications TECHFIELDS PHARMA CO., LTD. (CN) 2023-01-03 US disclosed
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO LTD (CN) 2021-11-18 US disclosed
WO-2021116820-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF BENOXAPROFEN AUROBINDO PHARMA LIMITED (IN) 2021-06-17 WO disclosed
US-9872846-B2 High penetration compositions and uses thereof TECHFIELDS PHARMA CO., LTD. (CN) 2018-01-23 US disclosed
US-20170209585-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO LTD (CN) 2017-07-27 US disclosed
US-20170209404-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF PREMIER RESEARCH INTERNATIONAL, LLC 2017-07-27 US disclosed
US-20090238763-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO., LTD. (CN) 2009-09-24 US disclosed
EP-2054384-A1 POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ARYL- AND HETEROARYLPROPIONIC ACIDS WITH VERY FAST SKIN PENETRATION RATE Techfields Biochem Co. Ltd (CN) 2009-05-06 EP disclosed
WO-2008020270-A1 POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ARYL- AND HETEROARYLPROPIONIC ACIDS WITH VERY FAST SKIN PENETRATION RATE TECHFIELDS BIOCHEM CO. LTD (CN) 2008-02-21 WO disclosed
US-4696929-A Derivative of piperazine having anti-allergic and anti-inflammatory action TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 1987-09-29 US disclosed
EP-0188803-A1 Piperazine derivative TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 1986-07-30 EP disclosed
US-4529737-A Analgesic and anti-inflammatory arylalkanoic acid phthalidyl esters and pharmaceutical compositions thereof RESFAR S.R.I. (IT) 1985-07-16 US disclosed
US-4416892-A ANTIALLERGENS LILLY INDUSTRIES LIMITED (GB) 1983-11-22 US disclosed
US-4362738-A ANTIINFLAMMATORIES DR. KARL THOMAE GMBH (DE) 1982-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170209404-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES HPSE 20/4885KDM4E 4795/4885MAPT 3194/4885
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES HPSE 20/4885KDM4E 4795/4885MAPT 3194/4885
US-11541029-B2 High penetration compositions and their applications SLC19A1, HIRA, SLC43A1 HPSE 4/4885KDM4E 4307/4885MAPT 1754/4885
US-20170209585-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES HPSE 20/4885KDM4E 4795/4885MAPT 3194/4885
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS SLC5A7, SLC19A1, SLC43A1 HPSE 29/4885KDM4E 2401/4885MAPT 2642/4885
US-20090238763-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES HPSE 20/4885KDM4E 4795/4885MAPT 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.